Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Boehringer Ingelheim
Farmers Insurance
Daiichi Sankyo
Mallinckrodt
McKinsey
Teva
US Army
Merck
Medtronic

Generated: August 16, 2017

DrugPatentWatch Database Preview

Oak Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for OAK PHARMS, and when can generic versions of OAK PHARMS drugs launch?

OAK PHARMS has fifteen approved drugs.

There are seven US patents protecting OAK PHARMS drugs on OAK PHARMS drugs in the past three years.

There are sixty-six patent family members on OAK PHARMS drugs in twenty-two countries.

Summary for Applicant: Oak Pharms

Patents:7
Tradenames:11
Ingredients:11
NDAs:15
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Oak Pharms Inc
COSOPT PF
dorzolamide hydrochloride; timolol maleate
SOLUTION/DROPS;OPHTHALMIC202667-001Feb 1, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Oak Pharms Inc
XOPENEX
levalbuterol hydrochloride
SOLUTION;INHALATION020837-001Mar 25, 1999ANRXYesYes► Subscribe► Subscribe ► Subscribe
Oak Pharms Inc
AZASITE
azithromycin
SOLUTION/DROPS;OPHTHALMIC050810-001Apr 27, 2007RXYesYes► Subscribe► Subscribe ► Subscribe
Oak Pharms Inc
BETIMOL
timolol
SOLUTION/DROPS;OPHTHALMIC020439-002Mar 31, 1995ATRXYesYes► Subscribe► Subscribe► Subscribe
Oak Pharms Inc
BETIMOL
timolol
SOLUTION/DROPS;OPHTHALMIC020439-001Mar 31, 1995ATRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Oak Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Oak Pharms Inc
COSOPT
dorzolamide hydrochloride; timolol maleate
SOLUTION/DROPS;OPHTHALMIC020869-001Apr 7, 1998► Subscribe► Subscribe
Oak Pharms Inc
XOPENEX
levalbuterol hydrochloride
SOLUTION;INHALATION020837-003Jan 30, 2002► Subscribe► Subscribe
Oak Pharms Inc
XOPENEX
levalbuterol hydrochloride
SOLUTION;INHALATION020837-002Mar 25, 1999► Subscribe► Subscribe
Oak Pharms Inc
XOPENEX
levalbuterol hydrochloride
SOLUTION;INHALATION020837-001Mar 25, 1999► Subscribe► Subscribe
Oak Pharms Inc
AZASITE
azithromycin
SOLUTION/DROPS;OPHTHALMIC050810-001Apr 27, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for OAK PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
tafluprost
Ophthalmic Solution0.0015%
ZIOPTAN
2/10/2016
levalbuterol tartrate
Inhalation Aerosol0.045 mg/actuation
XOPENEX
2/27/2012
azithromycin
Ophthalmic Solution1%
AZASITE
3/3/2011
levalbuterol hydrochloride
Inhalation Solution0.0025
XOPENEX
5/23/2006
dorzolamide hydrochloride and timolol maleate
Ophthalmic Solution2%/0.5%
COSOPT
10/11/2005
levalbuterol hydrochloride
Inhalation Solution0.0103%, 0.021% and 0.042%
XOPENEX
6/20/2005

Non-Orange Book Patents for Oak Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,985,920 Difluoroprostaglandin derivatives and their use► Subscribe
6,699,492 Quinolone carboxylic acid compositions and related methods of treatment► Subscribe
6,685,958 Quinolone carboxylic acid compositions and related methods of treatment► Subscribe
7,732,415Topical treatment or prevention of ocular infections► Subscribe
7,749,970Topical treatment of prevention of ocular infections► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Oak Pharms Drugs

Country Document Number Estimated Expiration
European Patent Office1028707► Subscribe
European Patent Office0925789► Subscribe
Canada2302379► Subscribe
World Intellectual Property Organization (WIPO)9922713► Subscribe
Japan4904621► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Oak Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0030France► SubscribePRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0850926/01Switzerland► SubscribePRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE: SWISSMEDIC 60548 27.01.2010
00C/001Belgium► SubscribePRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306
90041Netherlands► SubscribePRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
/1999Austria► SubscribePRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
US Department of Justice
AstraZeneca
Julphar
Deloitte
Mallinckrodt
Fuji
Medtronic
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot